HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26908870.
- Also identified by DOI 10.2337/db15-0519 and PMC identifier 4839204.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hypoxia-inducible factor (HIF)-1 mediates hypoxia- and chronic kidney disease-induced fibrotic events. Here, we assessed whether HIF-1 blockade attenuates the manifestations of diabetic nephropathy in a type 1 diabetic animal model, OVE26. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole], an HIF-1 inhibitor, reduced whole kidney glomerular hypertrophy, mesangial matrix expansion, extracellular matrix accumulation, and urinary albumin excretion as well as NOX4 protein expression and NADPH-dependent reactive oxygen species production, while blood glucose levels remained unchanged. The role of NOX oxidases in HIF-1-mediated extracellular matrix accumulation was explored in vitro using glomerular mesangial cells. Through a series of genetic silencing and adenoviral overexpression studies, we have defined GLUT1 as a critical downstream target of HIF-1α mediating high glucose-induced matrix expression through the NADPH oxidase isoform, NOX4. Together, our data suggest that pharmacological inhibition of HIF-1 may improve clinical manifestations of diabetic nephropathy.
Medical subject headings
- Diabetes Mellitus, Type 1
- Diabetic Nephropathies
- Glucose Transporter Type 1
- Hypoxia-Inducible Factor 1, alpha Subunit
- Kidney
- NADPH Oxidases
- Renal Insufficiency